Form 4: PROCEPT BioRobotics Director Receives Equity Compensation Grant

PROCEPT BioRobotics Corp (PRCT) announced that Director Amy M. Dodrill was granted 1,538 restricted stock units (RSUs) and 2,771 stock options as part of her compensation.

Summary

• Amy M. Dodrill, a Director of PROCEPT BioRobotics Corp (PRCT), acquired 1,538 shares of Common Stock in the form of Restricted Stock Units (RSUs) on June 10, 2025.
• Each RSU represents a contingent right to receive one share of Common Stock, vesting in full on the earlier of the one-year anniversary of the grant date or the date of the next annual meeting following the grant date, subject to continued service.
• Following this transaction, Ms. Dodrill beneficially owns 7,626 shares of Common Stock directly.
• Additionally, Ms. Dodrill was granted 2,771 stock options on June 10, 2025, with an exercise price of $64.23 per share.
• These stock options also vest in full on the earlier of the one-year anniversary of the grant date or the date of the next annual meeting following the grant date, subject to continued service.
• The stock options have an expiration date of June 9, 2035.
• Following this grant, Ms. Dodrill beneficially owns 2,771 derivative securities (stock options) directly.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it reflects standard corporate governance practices for director compensation, aligning interests and promoting retention. It is a routine filing and does not indicate any significant positive or negative operational or financial news beyond the compensation itself.

Positives

• The grant of Restricted Stock Units (RSUs) and stock options to a director aligns management's interests with those of shareholders, incentivizing long-term performance and value creation.
• Equity compensation is a common method for retaining experienced directors and motivating their continued service to the company.

Negatives

• The issuance of new equity awards, once vested and exercised, can lead to a minor dilutive effect on existing shareholders, though this is standard for equity compensation plans.

Risks

• The vesting of both the RSUs and stock options is subject to the director's continued service through the applicable vesting date, meaning the awards could be forfeited if service ceases before vesting.

Future Outlook

The vesting schedules for both the RSUs and stock options indicate an expectation of continued service from Director Amy M. Dodrill for at least one year or until the next annual meeting, aligning her incentives with the company's future performance.

Industry Context

The granting of equity compensation, such as RSUs and stock options, to directors is a standard practice across publicly traded companies, particularly in the medical technology and robotics sectors, to attract, retain, and incentivize key personnel by aligning their financial interests with long-term shareholder value.

Comparison to Industry Standards

• The structure of the equity grants, including RSUs and stock options with service-based vesting, is consistent with common compensation practices observed in the medical device and robotics industries.
• The vesting period tied to either a one-year anniversary or the next annual meeting is a typical approach for director equity awards, similar to companies like Intuitive Surgical (ISRG) or Stryker (SYK) for their non-employee directors.

Corporate Governance

Related Party Transactions

• The equity grants to Director Amy M. Dodrill constitute a related party transaction, as she is an insider of the company. This is a standard form of compensation and is disclosed as required by SEC regulations.

Stakeholder Impact

• Shareholders: The grants align the director's financial incentives with shareholder value creation, but also introduce a minor potential for future dilution upon vesting and exercise.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• The granted Restricted Stock Units (RSUs) and stock options will vest according to their specified schedules, contingent on continued service.
• The director may exercise the vested stock options at the specified exercise price prior to their expiration date.

Key Dates

Recommendation

Keywords

PROCEPT BioRobotics, PRCT, SEC Form 4, Insider Transaction, Director Compensation, Restricted Stock Units, RSUs, Stock Options, Equity Grant, Corporate Governance